BDR 57-1104
SB 344

EXECUTIVE AGENCY

FISCAL NOTE

AGENCY'S ESTIMATES

Date Prepared: March 26, 2025

Agency Submitting: Department of Health and Human Services, Health Care Financing and Policy

Items of Revenue or Expense, or Both	Fiscal Year 2024-25	Fiscal Year 2025-26	Fiscal Year 2026-27	Effect on Future Biennia
Medical Services (Expense) (Expense)		$2,469,837	$5,394,559	$10,789,118
Systems Cost (MMIS) (Expense) (Expense)		$44,800		
Total	0	$2,514,637	$5,394,559	$10,789,118

Explanation (Use Additional Sheets of Attachments, if required)

If enacted, this bill would have a fiscal impact on the Division. Specifically, the bill would require Nevada Medicaid to cover fetal blood tests for chromosomal abnormalities, as well as genetic carrier testing for cystic fibrosis (CF) and spinal muscular atrophy (SMA) during pregnancy.

Based on a fiscal analysis by DHCFP, the bill would result in a total of $2,695,795 in new General Fund expenditures in the upcoming biennium. $11,200 of these expenditures would be used to fund systems-related changes to add these requests.

Assuming federal financial participation is available, the medical claims cost for these services would incur a total of $2,684,595 new General Fund expenditures. This fiscal analysis assumes that 50% of pregnant women covered by Medicaid would utilize these tests, given that 70% of current pregnant Medicaid members receive prenatal ultrasounds currently. Utilization of carrier tests is doubled to account for partners who are also eligible to also receive the tests. Notably, the CPT codes used in this analysis comprise of pre-symptomatic genetic tests used for the purposes of screening only.

In sum, adding coverage of these tests would result in $853,082 in new General Fund costs for Medicaid for FY26 and $1,842,713 in FY27. Additionally, $5,211,354 would be paid for with federal Title XIX funds in the FY26-27 biennium.

Name Stacie Weeks

Title Administrator

GOVERNOR'S OFFICE OF FINANCE COMMENTS

Date Thursday, March 20, 2025

The agency's response appears reasonable.

Name Tiffany Greenameyer

Title Director

Fiscal Impact Analysis

Division of Health Care Financing and Policy
SB344 Prenatal Testing
Analysis Summary

Estimated Fiscal Impact FY24-FY25 Biennium

State Fiscal Year	Total Computable	Federal Funds	General Fund	County Funds
FY24	$0	$0	$0	$0
FY25	$0	$0	$0	$0
Total	$0	$0	$0	$0

Estimated Fiscal Impact FY26-FY27 Biennium

State Fiscal Year	Total Computable	Federal Funds	General Fund	County Funds
FY26	$2,469,837	$1,627,313	$841,882	$642
FY27	$5,394,559	$3,550,441	$1,842,713	$1,405
Total	$7,864,396	$5,177,754	$2,684,595	$2,047

Utilization **50%**

Description of Budget Concept

NV Medicaid would be required to cover fetal blood tests for chromosomal abnormalities, as well as genetic carrier testing for cystic fibrosis (CF) and spinal muscular atrophy (SMA) during pregnancy. Testing would need to be completed without a PA.

Note: The bill does not mandate coverage of carrier screening for HMO, MCO or other insurers in Nevada. ONLY fetal genetic testing is required for those other insurers, and is already a covered service.

Methodology

1) Fee-For-Service (FFS) utilization and managed care encounter were captured by running a report out of the MMIS using the following parameters for this provider type/service:
SFY24 (07/01/2023 - 06/30/2024) Incurred with Runoff, Net Allowed Amount

2) Patient by Category counts were captured by running a report out of the MMIS to include FFS patients and Managed Care (MCO) patients.

3) Multipled patient count by two to account for both parents, as they are eligible for the carrier tests.

4) Combined tests associated with codes 81220+81329+81420. Multipled the combined rate by the assumed utilization.

5) Total computable expenditures are grown forward based on the DHHS Office of Analytics caseload projections.

6) FMAP rates were applied to determine the federal share of estimated costs. Note that the COVID-19 enhanced FMAP (+6.2%) for Medicaid is used through March 31, 2023. Enhanced COVID FMAP amounts are tiered down across CY 2023 to align with the 2023 Federal FY Omnibus Appropriations Bill, which allows the following enhanced FMAP amounts: 6.2% (CY23 Q1); 5.0% (CY23 Q2); 2.5% (CY23 Q3); 1.5% (CY23 Q4).